The tracker below provides information on accelerated assessment requests for planned marketing authorization applications (MAAs) that have come before the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
This latest update reflects Sanofi's failure to secure accelerated assessment for avalglucosidase alfa. Also see "Sanofi Files New...





